Summary
7.88 0.02(0.25%)09/06/2024
Annovis Bio Inc (ANVS)
Annovis Bio Inc (ANVS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.25 | -6.86 | -5.63 | 18.41 | -15.72 | -31.36 | 0.00 | -17.83 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.88 | |
| Open | 7.77 | |
| High | 7.92 | |
| Low | 7.45 | |
| Volume | 124,851 | |
| Change | 0.02 | |
| Change % | 0.25 | |
| Avg Volume (20 Days) | 167,128 | |
| Volume/Avg Volume (20 Days) Ratio | 0.75 | |
| 52 Week Range | 4.53 - 22.49 | |
| Price vs 52 Week High | -64.96% | |
| Price vs 52 Week Low | 73.95% | |
| Range | 1.42 | |
| Gap Up/Down | -0.81 | |
Fundamentals | ||
| Market Capitalization (Mln) | 103 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 70.00 | |
| Book Value | 5.7440 | |
| Earnings Per Share | -1.4030 | |
| EPS Estimate Current Quarter | -0.4400 | |
| EPS Estimate Next Quarter | -0.4200 | |
| EPS Estimate Current Year | -1.6700 | |
| EPS Estimate Next Year | -2.7700 | |
| Diluted EPS (TTM) | -1.4030 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.2306 | |
| Return on equity (TTM) | -0.3693 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.6629 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 8,100,570 | |
| Shares Float | 5,520,295 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 30.67 | |
| Institutions (%) | 18.55 | |
09/05 08:00 EST - globenewswire.com
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024.
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024.
08/06 08:00 EST - globenewswire.com
Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alzheimer's disease.
Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alzheimer's disease.
07/03 10:10 EST - zacks.com
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.
07/02 16:45 EST - investorplace.com
Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?
Annovis Bio (NYSE: ANVS ) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson's treatment, buntanetap. Early results show that its buntanetap is both safe and effective in treating patients with early Parkinson's, helping them retain and improve both motor and non-motor activities and cognitive functions.
Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?
Annovis Bio (NYSE: ANVS ) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson's treatment, buntanetap. Early results show that its buntanetap is both safe and effective in treating patients with early Parkinson's, helping them retain and improve both motor and non-motor activities and cognitive functions.
07/02 13:57 EST - marketwatch.com
Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial
Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap.
Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial
Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap.
06/26 08:00 EST - globenewswire.com
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.
06/11 08:00 EST - globenewswire.com
Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), today announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD.
Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), today announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD.
05/28 10:56 EST - zacks.com
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
05/21 07:30 EST - globenewswire.com
Annovis Announces New Publication in a Peer-Reviewed Journal
MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases.
Annovis Announces New Publication in a Peer-Reviewed Journal
MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases.
05/17 11:00 EST - businesswire.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company's possible violations of federal securities laws. On April 29, 2024, Annovis announced that its Alzheimer's drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the total planned patients, indicating that the drug failed to show statistical.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company's possible violations of federal securities laws. On April 29, 2024, Annovis announced that its Alzheimer's drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the total planned patients, indicating that the drug failed to show statistical.
05/16 19:02 EST - businesswire.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Annovis investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws,.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Annovis investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws,.
05/16 15:09 EST - businesswire.com
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 29, 2024, Annovis announced that its Alzheimer's drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the.
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 29, 2024, Annovis announced that its Alzheimer's drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the.
05/13 07:30 EST - globenewswire.com
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results.
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results.
05/09 20:43 EST - seekingalpha.com
Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box
Recent results suggest that buntanetap, along with other treatments, does not significantly improve the condition of moderate Alzheimer's disease patients.
Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box
Recent results suggest that buntanetap, along with other treatments, does not significantly improve the condition of moderate Alzheimer's disease patients.
05/09 07:30 EST - globenewswire.com
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson's disease (PD). Topline efficacy data is expected in June.
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson's disease (PD). Topline efficacy data is expected in June.
05/06 07:30 EST - globenewswire.com
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer's study and sharing next steps.
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer's study and sharing next steps.
04/29 10:30 EST - reuters.com
Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial
Annovis Bio said on Monday that its Alzheimer's treatment showed significantly higher improvement in cognition in Alzheimer's patients during a mid-stage trial.
Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial
Annovis Bio said on Monday that its Alzheimer's treatment showed significantly higher improvement in cognition in Alzheimer's patients during a mid-stage trial.
04/29 10:10 EST - globenewswire.com
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's disease (PD), today announced the data from its Phase II/III Alzheimer study of buntanetap in mild to moderate AD patients. Based on these data, the Company plans to conduct a pivotal Phase III trial in biomarker-positive early AD patients.
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's disease (PD), today announced the data from its Phase II/III Alzheimer study of buntanetap in mild to moderate AD patients. Based on these data, the Company plans to conduct a pivotal Phase III trial in biomarker-positive early AD patients.
04/24 10:56 EST - zacks.com
Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
04/08 10:56 EST - zacks.com
Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 218.9% in Annovis Bio (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 218.9% in Annovis Bio (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.